PDF Innovation Development and Access pathway

The PDF Innovation Development and Access pathway—IFPMA’s IDAP whitepaper dated December 2025—maps how medicines and vaccines move from laboratory discovery to point-of-care delivery. It organizes the journey into four phases and argues that governments, not manufacturers alone, control many bottlenecks. This brief pairs that framing with WHO and EMA primary programs that IDAP itself treats as policy enablers.

Key Takeaways

• IDAP defines four phases: R&D; regulatory registration and life-cycle management; listing/guidelines/procurement/reimbursement; and health service delivery.
• IFPMA positions governments as uniquely able to prioritize health through policy and budget decisions that enable timely access.
• Cited enablers include regulatory reliance, streamlined WHO prequalification, and updated essential medicines lists and clinical guidelines.
• IDAP is a framing paper, not a clinical efficacy dataset; it does not publish country wait times or approval rates as audited trial endpoints.

What does the PDF Innovation Development and Access paper claim?

IFPMA’s IDAP paper argues that innovative medicines and vaccines often fail to reach people in timely volumes, especially in lower-resource settings. Manufacturers are only one actor. Regulatory approvals, procurement mechanisms, and health workforce capacity depend on other stakeholders. The paper’s goal is a shared baseline of bottlenecks from laboratory to patient.

IDAP explicitly includes both recently introduced on-patent products and older products with generic or biosimilar competition after patent expiry. That breadth matters for access debates that otherwise focus only on launch products.

What are the four IDAP phases?

Most medicines and vaccines, per IDAP, follow four common phases even when country-specific steps differ:

• Research and Development and the innovation ecosystem (discovery through Phase I–IV)
• Regulatory processes, product registration, and life-cycle management
• Listing, treatment guidelines, procurement, and payment or reimbursement
• Health service delivery: distribution, supply chain, workforce, diagnostics or referral networks, treatment, and follow-up

Delays at any stage can block patient access even after a successful pivotal trial. That is why end-to-end mapping is the paper’s organizing idea.

How do WHO programs map to IDAP’s regulatory and listing phases?

IDAP’s accompanying pathway chart lists fit-for-purpose harmonized regulatory systems, regulatory reliance, and streamlined WHO prequalification as registration-phase enablers. WHO’s Regulation and Prequalification work is the public program that assesses quality, safety, and efficacy for procurement agencies and national regulators that rely on it.

For listing and guidelines, IDAP calls for updated and implemented essential medicines lists and clinical guidelines. The WHO Model Lists of Essential Medicines remain the reference framework many national EMLs adapt. IDAP also cites WHO’s broader 2025–2030 access roadmap as a parallel holistic framing, without replacing WHO’s own governance.

Where do EMA registration facts fit?

Centralized EMA marketing authorisation is a concrete example of the IDAP regulatory phase in high-income and EU-linked markets. Authorisation is necessary but not sufficient for access: listing, HTA, procurement, and delivery still follow. That sequence matches IDAP’s insistence that registration alone does not equal patient delivery.

For global health teams, the practical translation is to track registration, EML/guideline status, reimbursement or tender inclusion, and last-mile delivery as four separate scorecards rather than a single “approved = available” flag.

What supporting evidence does IDAP invoke?

The paper references a July 2025 IQVIA analysis of access pathways and bottlenecks in 18 LMICs, reporting systemic barriers that limit access to both newly launched and established products. It also notes Access to Medicine Foundation findings that 14 of 20 companies (70%) have systematic access-planning policies for pipeline candidates from Phase II onwards. Those figures are secondary citations inside an industry paper and should be verified against the underlying reports before use in investment memos.

What remains unproven

IDAP does not provide randomized evidence that adopting its four-phase map shortens time to patient by a stated number of days. It does not publish audited national reimbursement wait times. It is an IFPMA perspective document. Claims that IDAP is a WHO standard, a regulatory requirement, or a guarantee of LMIC access are not supported and are omitted here.

Related NovaPharma coverage

• WHO revised biosimilar guidelines for global access
• IFPMA whitepaper on assessment reports and regulatory reliance
• EFPIA Patients W.A.I.T. Indicator Europe access delays

Frequently Asked Questions

What is the PDF Innovation Development and Access pathway?

IDAP is IFPMA’s December 2025 framework describing four linked phases: R&D and the innovation ecosystem; regulatory registration and life-cycle management; listing, guidelines, procurement, and reimbursement; and health service delivery to patients.

Which policy enablers does IDAP emphasize for regulators?

The pathway chart highlights fit-for-purpose harmonized regulatory systems, implementation of regulatory reliance, and streamlined WHO prequalification as enablers in the registration phase, alongside updated essential medicines lists and clinical guidelines later in the pathway.

Does IDAP replace WHO or EMA access programs?

No. IDAP is an industry framing paper. Operational programs such as WHO prequalification, WHO Essential Medicines Lists, and EMA marketing authorisation remain the primary public mechanisms that determine whether products can be registered, procured, and delivered.

Primary Sources

1. WHO Regulation and Prequalification
2. WHO Model Lists of Essential Medicines
3. EMA marketing authorisation overview